Article in Pediatric blood & cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Rachel D HarrisDepartment of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-8191-5477
Olga A TaylorDepartment of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
Kimberly P RaghubarDepartment of Pediatrics, Division of Psychology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-9332-181X
Mariana Matheus GonzalezDepartment of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-0947-104X
Mark ZobeckDepartment of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0003-0997-906X
M Monica GramatgesDepartment of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
Karen R RabinDepartment of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
Michael E ScheurerDepartment of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
Austin L BrownDepartment of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-5802-5073
Funding
PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAMK12CA090433 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CARL E ALLEN, Donald W. Parsons · 2002 to 2026
$18.5M
The PreVAIL-kIds Common ProtocolR33HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI ALLEN, CARL E, ANNAPRAGADA, ANANTH V · 2023 to 2023
$6.3M
Improving Outcome Disparities for Latino Children and Adolescents with Acute Lymphoblastic LeukemiaP20CA262733 · NCI · BAYLOR COLLEGE OF MEDICINE · PI GRAMATGES, MARIA MONICA · 2021 to 2023
$3.2M
See, Reach, Treat Tumor-Optimized Transarterial Chemoembolization DrugDeliveryR01CA160771 · NCI · YALE UNIVERSITY · PI GESCHWIND, JEAN-FRANCOIS H, LIN, MINGDE · 2011 to 2015
$2.6M
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute LeukemiaR01CA272981 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Austin L Brown, Avner Meoded · 2023 to 2026
$2.5M
An Integrative Approach to Evaluate Neurocognitive Disparities in Latinos Undergoing Treatment for Childhood Leukemia.R01CA261879 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Austin L Brown, Kimberly Pauline Raghubar · 2022 to 2026
$2.5M
Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric CancerR01CA284531 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Chad Daniel Huff, Philip Lupo · 2023 to 2026
$1.9M
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic LeukemiaK07CA218362 · NCI · BAYLOR COLLEGE OF MEDICINE · PI BROWN, AUSTIN L · 2018 to 2022
$758k
Cancer Prevention and Research Institute of Texas RP160771Cancer Prevention and Research Institute of Texas RP190132Cancer Prevention and Research Institute of Texas RP230026Leukemia Research FoundationLeukemia Research Foundation Hollis Brownstein Research Grants ProgramNational Institutes of Health National Cancer Institute K07CA218362National Institutes of Health National Cancer Institute K12CA090433National Institutes of Health National Cancer Institute P20CA262733National Institutes of Health National Cancer Institute R01CA272981NCI NIH HHS K07 CA218362NCI NIH HHS K12 CA090433NCI NIH HHS P20 CA262733NCI NIH HHS R01 CA261879NCI NIH HHS R01 CA272981NCI NIH HHS R01 CA284531NICHD NIH HHS R33 HD105593St. Baldrick's FoundationSt. Baldrick's Foundation Consortium Research Grant 522277
6 · The paper itself
Abstract
Methotrexate is a critical component of curative chemotherapy for pediatric acute lymphoblastic leukemia (ALL), but is associated with neurotoxicity. Information on long-term outcomes following an acute neurotoxic event is limited. Therefore, this report compares neurocognitive performance more than 12 months post diagnosis (mean = 4 years) between ALL patients with (n = 25) and without (n = 146) a history of acute neurotoxicity. Compared to children with no documented on-treatment neurotoxic event, children who experienced a neurotoxic event during treatment exhibited poorer performance on measures of fine motor function (p = .02) and attention (p = .02). Children with ALL who experience acute neurotoxicity may be candidates for early neuropsychological screening and intervention.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. · full record | OpenQuestion